Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E102.89 EPS (ttm)3.49 Insider Own1.00% Shs Outstand101.07M Perf Week1.35%
Market Cap36.29B Forward P/E29.15 EPS next Y12.32 Insider Trans-3.28% Shs Float74.40M Perf Month2.76%
Income396.30M PEG4.80 EPS next Q2.57 Inst Own75.10% Short Float4.71% Perf Quarter17.62%
Sales2.50B P/S14.52 EPS this Y-43.60% Inst Trans-0.05% Short Ratio4.12 Perf Half Y9.04%
Book/sh23.60 P/B15.22 EPS next Y21.80% ROA12.90% Target Price366.11 Perf Year21.06%
Cash/sh8.08 P/C44.43 EPS next 5Y21.44% ROE19.30% 52W Range257.69 - 369.31 Perf YTD30.47%
Dividend- P/FCF70.58 EPS past 5Y42.20% ROI19.20% 52W High-2.76% Beta0.98
Dividend %- Quick Ratio5.20 Sales past 5Y54.60% Gross Margin88.20% 52W Low39.35% ATR7.44
Employees2469 Current Ratio5.50 Sales Q/Q45.50% Oper. Margin34.30% RSI (14)63.16 Volatility2.13% 2.03%
OptionableYes Debt/Eq0.22 EPS Q/Q3.80% Profit Margin15.90% Rel Volume0.78 Prev Close355.47
ShortableYes LT Debt/Eq0.22 EarningsAug 05 BMO Payout0.00% Avg Volume850.06K Price359.10
Recom2.10 SMA202.68% SMA508.00% SMA20016.89% Volume659,623 Change1.02%
02-Sep-14Reiterated Brean Capital Buy $380 → $390
06-Aug-14Reiterated RBC Capital Mkts Outperform $349 → $373
21-Jul-14Initiated Argus Buy $375
16-Apr-14Initiated Canaccord Genuity Buy $350
13-Feb-14Downgrade Oppenheimer Outperform → Perform $310 → $325
30-Sep-13Reiterated Oppenheimer Outperform $300 → $310
22-Aug-13Initiated Oppenheimer Outperform $300
17-May-13Initiated UBS Neutral $290
06-May-13Reiterated RBC Capital Mkts Outperform $270 → $286
06-May-13Reiterated Barclays Overweight $275 → $305
02-May-13Reiterated Barclays Overweight $194 → $275
28-Feb-13Initiated Barclays Overweight $194
21-Dec-12Reiterated RBC Capital Mkts Outperform $171 → $190
14-Feb-12Reiterated RBC Capital Mkts Outperform $83 → $130
10-Jan-12Upgrade Robert W. Baird Neutral → Outperform $56 → $81
05-Dec-11Reiterated Brean Murray Buy $78 → $67
28-Jul-11Upgrade RBC Capital Mkts Sector Perform → Outperform $70 → $70
09-May-11Reiterated Needham Buy $49 → $60
29-Apr-11Reiterated Barclays Capital Overweight $64 → $72
29-Apr-11Downgrade RBC Capital Mkts Outperform → Sector Perform $70 → $70
17-Sep-14 03:30PM  Regeneron Gets Breakthrough Therapy Status for Eylea Zacks
16-Sep-14 12:12PM  Stocks Erase Modest Gains; Netflix Gaps Below 50-Day Line at Investor's Business Daily
07:00AM  EYLEA® (aflibercept) Injection Receives FDA Breakthrough Therapy Designation for Diabetic Retinopathy in Patients with Diabetic Macular Edema PR Newswire
15-Sep-14 05:06PM  Biotech still place to be: Pro CNBC
14-Sep-14 07:01PM  Costly eye drug and far cheaper alternative have similar side effects -study Reuters
11-Sep-14 02:46PM  Stocks Show Modest Losses; Biotechs Pressured Again at Investor's Business Daily
10:02AM  Trading Guidelines for Amgen, Biogen Idec, Gilead, 3 Other Biotechs at TheStreet
10-Sep-14 06:09PM  Like Apple, these firms satisfy unmet need: Cramer at CNBC
02:53PM  Stocks Hold Modest Gains; FleetCor Reverses Higher at Investor's Business Daily
01:25PM  Stocks Turn Higher After Soft Start; U.S. Silica Jumps at Investor's Business Daily
08-Sep-14 03:45PM  Bayer/Regeneron Looking for Eylea Label Expansion in Japan Zacks
05-Sep-14 06:33PM  Jim Cramer's fantasy stock portfolio at CNBC
06:00AM  Jim Cramer's Top Stock Picks: MMM TSLA NFLX REGN DECK at TheStreet
04-Sep-14 08:00PM  [video] Regeneron Rises, Norwegian Cruises and CVS Health Quits the Habit at TheStreet
07:45PM  Jim Cramer's 'Mad Money' Recap: Stocks Are the Rational Choice at TheStreet
07:07PM  Jim Cramer's 'Mad Money' Recap: Stocks Are the Rational Choice at TheStreet
06:25PM  Cramer: Football lovers make good stock pickers? at CNBC
06:25PM  [video] Cramer's WR stock pick: TSLA, NFLX, REGN at CNBC
05:00PM  Amgen Seeks EU Approval for PCSK9 Inhibitor Evolocumab Zacks
11:01AM  Celgene: Good Data But What About the Patent Challenges? at Barrons.com
08:32AM  The Zacks Analyst Blog Highlights: United Therapeutics, Repros Therapeutics, Amgen, Regeneron and Aegerion Zacks
03:00AM  Regeneron Announces Submission of Application for EYLEA® (aflibercept) Injection in Japan for Macular Edema Following Branch Retinal Vein Occlusion PR Newswire
03-Sep-14 10:32AM  Sanofi: First Heart Disease, Now Dengue Fever at Barrons.com
09:10AM  Biotech Stock Roundup: United Therapeutics Up on Court Ruling, Amgen Files PCSK9 Inhibitor Zacks
06:26AM  [$$] Regeneron Shares Seen Approaching $400 at Barrons.com
02-Sep-14 06:07PM  Cramer: Twitter and other 'irresistible' stocks at CNBC
06:04PM  Novartis, Regeneron Shares Advance To New Highs On Updated Drug News Investor's Business Daily
04:19PM  Why Jim Cramer Likes Regeneron (REGN) Stock Over Sanofi (SNY) at TheStreet
03:44PM  [video] The cholesterol race at CNBC
03:30PM  Regeneron/Sanofi Presents Encouraging Alirocumab Data Zacks
03:04PM  [video] Jim Cramer Says Regeneron is a Better Way to Play it Than Sanofi at TheStreet
01:34PM  [video] Biotech's $10 billion opportunity at CNBC
01:03PM  Today's Top Performers In Drugs at TheStreet
01:00PM  [video] American doctor tests for Ebola: Report at CNBC
12:10PM  Regeneron: Solid Trial Takes Targets Up, Up, Up at Barrons.com
11:19AM  Novartis, Regeneron Hit New Highs On Cardio Drugs at Investor's Business Daily
11:13AM  How Will Regeneron Pharmaceuticals (REGN) Stock Be Affected By This Coverage? at TheStreet
10:48AM  Jim Cramer's Mad Dash: Regeneron to $400; Conn's a No-Touch at TheStreet
10:43AM  Thin Gains Quickly Turn Mixed; Regeneron, Staples Surge Ahead at Investor's Business Daily
10:29AM  Cramer sees 'breakout' for this stock at CNBC
09:53AM  [video] Regeneron Shares Trend Higher on Cholesterol-Lowering Results at TheStreet
09:36AM  UPDATE: Morgan Stanley Reiterates On Regeneron Pharmaceuticals Ahead Of Conference Call Benzinga
09:22AM  [video] Cramer's Mad Dash: Regeneron rising at CNBC
08:17AM  [video] Race for cholesterol drugs at CNBC
08:00AM  Morning Movers: Dollar General Ups Bid for Family Dollar; Staples Gains on Upgrade at Barrons.com
31-Aug-14 06:36PM  Cholesterol Drug Halves Heart Attack and Stroke in Early Test at New York Times
01:28PM  Early Hint At Cardiovascular Outcomes With Sanofi's and Regeneron's Rapidly Advancing Cholesterol Drug at Forbes
03:00AM  Early data suggest Sanofi, Regeneron drug may halve heart risk Reuters
03:00AM  Sanofi-Regenerons Amgen Drug Rival Cuts Cholesterol at Bloomberg
03:00AM  Sanofi and Regeneron Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress 2014 PR Newswire
03:00AM  Regeneron and Sanofi Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress 2014 PR Newswire
29-Aug-14 05:30PM  Regeneron Pharmaceuticals' Pipeline Progress Raises Costs Zacks
03:12PM  Nasdaq, S&P 500 Rise In Lackluster Session; Tesla Gains at Investor's Business Daily
01:35PM  Nasdaq Leads Quiet, Pre-Holiday Session; NXP Breaks Out at Investor's Business Daily
28-Aug-14 06:42PM  Amgen edges up on trial results Investor's Business Daily
03:17PM  Amgen: Why Its New Drug Application is a Big Deal at Barrons.com
03:17PM  Amgen: Why Its New Drug Application is a Bid Deal at Barrons.com
03:03PM  Stocks Indexes Fall Modestly, Shaking Off Ukraine Unrest at Investor's Business Daily
10:15AM  Insider Trading Alert - SEAS, REGN And ALTR Traded By Insiders at TheStreet
27-Aug-14 06:17PM  [$$] Drug Maker in High-Stakes Race With Rivals at The Wall Street Journal
04:20PM  BioMarin Cuts '14 Revenue View after Voucher Sale Evaluation Zacks
01:03PM  3 Drugs Stocks Dragging The Industry Down at TheStreet
09:41AM  [$$] Drug Maker in High-Stakes Race With Rivals at The Wall Street Journal
08:56AM  Regeneron (REGN) is in Overbought Territory: What's Next? Zacks
08:33AM  [$$] Drug Maker in High-Stakes Race With Rivals at The Wall Street Journal
12:32AM  [$$] Drug Maker in High-Stakes Race With Rivals at The Wall Street Journal
12:14AM  [$$] Drug Maker in High-Stakes Race With Rivals at The Wall Street Journal
26-Aug-14 11:15PM  [$$] Drug Maker in High-Stakes Race With Rivals at The Wall Street Journal
09:18PM  [$$] Drug Maker in High-Stakes Race With Rivals at The Wall Street Journal
06:10PM  [$$] Drug Maker in High-Stakes Race With Rivals at The Wall Street Journal
02:06PM  [video] Pharma CEO: Dont Follow the Markets at MarketWatch
25-Aug-14 10:27AM  Today's Momo Momentum Stock Is Regeneron Pharmaceuticals (REGN) at TheStreet
09:49AM  [video] Gilead 'the drug story': Cramer at CNBC
01:00AM  Regeneron and Sanofi to Present Results from Four Phase 3 Alirocumab Trials in Hot Line Session at ESC Congress 2014 PR Newswire
21-Aug-14 01:25PM  Qihoo, Regeneron Among 5 Stocks With Top Fundamentals at Investor's Business Daily
01:25PM  Qihoo Among 5 Stocks With Top Fundamentals at Investor's Business Daily
19-Aug-14 10:00AM  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to Ring The NASDAQ Stock Market Opening Bell GlobeNewswire
09:30AM  Regeneron Announces Upcoming 2014 Investor Conference Presentations PR Newswire
07:07AM  [video] Hot biotech drugs at CNBC
18-Aug-14 01:46PM  Jazz, Celgene Lead Top 4 Drugmaker Profit Margins at Investor's Business Daily
09:16AM  [video] Cramer: Market about Russia-Ukraine at CNBC
17-Aug-14 10:37PM  Regeneron CEO: How I became a billionaire at CNNMoney.com
14-Aug-14 08:33PM  [video] Eyeball injections equal eye-popping profits at CNNMoney.com
03:10PM  [video] Red hot biotech stocks at CNBC
13-Aug-14 06:08PM  Cramer: Is Street preparing for the worst? at CNBC
12-Aug-14 04:20PM  Regeneron's Eye Drug Eylea Cleared in the EU for DME Zacks
01:04PM  REGENERON PHARMACEUTICALS INC Financials EDGAR Online Financials
11-Aug-14 04:46PM  Markets Marginally Higher On Light Volume And Encouraging Geopolitical Developments Benzinga
09:19AM  [video] Cramer's Mad Dash: Tesla breaking out at CNBC
02:30AM  EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME) PR Newswire
07-Aug-14 08:38AM  Take Two Interactive, Loews, Amgen, Vertex and Regeneron highlighted as Zacks Bull and Bear of the Day Zacks
06-Aug-14 01:23PM  Celgene: Five Reasons to Be Bullish at Barrons.com
11:00AM  Biotech Stock Roundup: Amgen Plans Job Cuts, Regeneron's Eylea Continues to Impress Zacks
05-Aug-14 06:30PM  4 Top Drugmakers Deliver Solid Doses Of Earnings Growth Investor's Business Daily
04:46PM  Ukraine Tension Prominent As Dow Suffers Triple Point Digit Loss; S&P 500 & Nasdaq Also Lower Benzinga
04:46PM  Ukraine Tension Prominent As Dow Suffers Triple Digit Loss; S&P 500 & NASDAQ Also Lower Benzinga
03:30PM  Deutsche Bank Raises Regeneron's Price Target To $425 Benzinga
02:50PM  Regeneron Misses on Earnings in Q2, Eylea Drives Sales Beat Zacks
01:05PM  Midday movers: Family Dollar Stores, Target & More at CNBC
10:43AM  Regeneron sales top forecast as Eylea picks up steam Reuters
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for treating cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage comprise EYLEA for the treatment of DME and macular edema ophthalmologic diseases; and ZALTRAP for oncology. The company's antibody-based clinical programs include various human monoclonal antibody product candidates, such as REGN88 for rheumatoid arthritis and non-infectious uveitis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis, asthma, and nasal polyposis; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; and REGN1033 for skeletal muscle disorders. It is also developing REGN1154, REGN1154, REGN1193, and REGN1908-1909 antibody product candidates, as well as REGN2176-3, an antibody that is co-formulated with EYLEA for use in ophthalmology. The company distributes its products through Rensselaer facilities and third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
VAGELOS P ROYChairman of the BoardSep 10Sale350.0710,3263,614,82392,947Sep 10 04:00 PM
VAGELOS P ROYChairman of the BoardSep 08Sale351.002702103,273Sep 10 04:00 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 27Option Exercise21.561,68136,2474,681Aug 28 02:39 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriAug 27Option Exercise314.315,7201,797,853505,720Aug 29 03:29 PM
Tessier-Lavigne MarcDirectorAug 27Option Exercise50.913,000152,7304,187Aug 27 05:02 PM
GOLDSTEIN JOSEPH LDirectorAug 27Sale350.312,000700,6204,000Aug 27 05:01 PM
Tessier-Lavigne MarcDirectorAug 27Sale352.203,0001,056,6001,187Aug 27 05:02 PM
Tessier-Lavigne MarcDirectorAug 26Option Exercise50.911,38770,6121,387Aug 27 05:02 PM
Aberman Michael SVP Strategy and Investor RelatAug 22Option Exercise24.003,00072,00018,600Aug 26 09:45 AM
Aberman Michael SVP Strategy and Investor RelatAug 19Sale350.003,6111,263,85015,600Aug 19 04:16 PM
Aberman Michael SVP Strategy and Investor RelatAug 18Option Exercise52.038,750455,26324,350Aug 19 04:16 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 18Option Exercise52.035,875305,6768,875Aug 18 04:04 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 18Sale353.005,8752,073,8753,000Aug 18 04:04 PM
BROWN MICHAEL SDirectorAug 15Option Exercise33.423,000100,2603,000Aug 18 04:02 PM
BROWN MICHAEL SDirectorAug 15Sale349.203,0001,047,6000Aug 18 04:02 PM
GOLDSTEIN JOSEPH LDirectorAug 14Sale347.652,000695,3006,000Aug 14 04:14 PM
VAGELOS P ROYChairman of the BoardAug 13Sale340.018,0282,729,600248,540Aug 14 04:15 PM
STAHL NEILSVP Research and Development SAug 11Sale339.9611,6463,959,20413,527Aug 11 04:04 PM
VAGELOS P ROYChairman of the BoardAug 11Sale340.059,3723,186,967256,568Aug 11 05:25 PM
STAHL NEILSVP Research and Development SAug 08Sale340.642,100715,34025,173Aug 08 04:49 PM
VAGELOS P ROYChairman of the BoardAug 08Sale340.332,600884,858265,940Aug 11 05:25 PM
VAGELOS P ROYChairman of the BoardAug 07Option Exercise9.49270,3522,565,640411,191Aug 11 05:25 PM
STAHL NEILSVP Research and Development SAug 07Sale340.49741252,30427,273Aug 08 04:49 PM
STAHL NEILSVP Research and Development SAug 06Option Exercise21.2535,000743,75048,527Aug 08 04:49 PM
GOLDSTEIN JOSEPH LDirectorAug 06Sale331.202,000662,4008,000Aug 06 04:11 PM
REGENERON PHARMACEUTICALS INC10% OwnerAug 05Buy17.00588,2359,999,9951,809,098Aug 05 05:39 PM
Van Plew Daniel PSVP & General Mgr Industrial OMay 23Sale295.935,3691,588,87215,441May 23 03:58 PM
Van Plew Daniel PSVP & General Mgr Industrial OMay 22Option Exercise21.2511,200238,00026,641May 23 03:58 PM
POON CHRISTINE ADirectorMay 21Buy291.9025574,435255May 23 10:43 AM
BAKER CHARLES ADirectorMar 24Option Exercise23.8415,000357,60024,000Mar 25 08:03 PM
BAKER CHARLES ADirectorMar 24Sale302.6715,0004,540,0019,000Mar 25 08:03 PM
BROWN MICHAEL SDirectorMar 17Option Exercise33.422,00066,84016,662Mar 18 05:09 PM
BROWN MICHAEL SDirectorMar 17Sale334.292,000668,57314,662Mar 18 05:09 PM
VAGELOS P ROYChairman of the BoardFeb 27Option Exercise12.7070,879899,952140,839Mar 03 09:10 AM
BROWN MICHAEL SDirectorFeb 27Sale335.001,000335,00014,662Feb 27 04:30 PM
BROWN MICHAEL SDirectorFeb 26Option Exercise57.111,00057,11015,662Feb 27 04:30 PM
GOLDSTEIN JOSEPH LDirectorFeb 25Sale338.861,000338,8600Feb 25 05:48 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrFeb 25Sale339.5511,8714,030,82363,102Feb 26 04:57 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrFeb 24Option Exercise64.9030,2271,961,74685,365Feb 26 04:57 PM
GILMAN ALFRED GDirectorFeb 21Option Exercise18.615,00093,0505,000Feb 24 04:12 PM
SING GEORGE LDirectorFeb 21Option Exercise15.8015,000237,000117,772Feb 24 04:12 PM
SING GEORGE LDirectorFeb 21Sale339.0015,0005,085,000112,772Feb 24 04:12 PM
GILMAN ALFRED GDirectorFeb 21Sale340.005,0001,700,0000Feb 24 04:12 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrFeb 21Sale336.5121,2587,153,60863,102Feb 24 04:11 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrFeb 20Option Exercise47.7950,6522,420,80593,102Feb 24 04:11 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 20Option Exercise21.253,00063,7503,000Feb 21 04:43 PM
GOLDSTEIN JOSEPH LDirectorFeb 20Sale326.991,000326,9891,000Feb 21 04:44 PM
Terifay Robert JSVP CommercialFeb 18Sale332.6812,8654,279,89320,029Feb 19 04:10 PM
Aberman Michael SVP Strategy and Investor RelatFeb 18Sale331.423,6481,209,03615,600Feb 19 04:12 PM
SING GEORGE LDirectorFeb 14Option Exercise9.1715,000137,550127,772Feb 19 04:11 PM
Aberman Michael SVP Strategy and Investor RelatFeb 14Option Exercise30.637,500229,72523,100Feb 19 04:12 PM
Terifay Robert JSVP CommercialFeb 14Option Exercise21.2527,795590,64447,824Feb 19 04:10 PM
SING GEORGE LDirectorFeb 14Sale324.0015,0004,860,000112,772Feb 19 04:11 PM
STAHL NEILSVP Research and Development SFeb 13Sale318.8222,6127,209,13624,391Feb 13 06:32 PM
STAHL NEILSVP Research and Development SFeb 12Option Exercise20.0654,5481,094,40664,391Feb 13 06:32 PM
SHOOTER ERIC MDirectorFeb 12Option Exercise89.4515,0001,341,75015,000Feb 13 07:38 PM
SHOOTER ERIC MDirectorFeb 12Sale320.5215,0004,807,8690Feb 13 07:38 PM
GOLDSTEIN JOSEPH LDirectorFeb 12Sale320.621,000320,6202,000Feb 13 04:06 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriFeb 12Sale320.3388,98728,504,9851,068,343Feb 13 04:03 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriFeb 11Option Exercise9.49189,4631,798,0041,257,806Feb 13 04:03 PM
GILMAN ALFRED GDirectorFeb 11Option Exercise18.615,00093,0505,000Feb 12 04:17 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 11Option Exercise30.635,819178,2365,819Feb 12 04:15 PM
GILMAN ALFRED GDirectorFeb 11Sale320.005,0001,600,0000Feb 12 04:17 PM
VAGELOS P ROYChairman of the BoardFeb 11Sale325.1011,4753,730,523103,275Feb 12 04:15 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 11Sale325.005,8191,891,1750Feb 12 04:15 PM
GILMAN ALFRED GDirectorJan 14Option Exercise18.615,00093,0505,000Jan 14 05:25 PM
McCorkle Douglas SVP Controller and Asst TreasurJan 14Sale290.004,0001,160,0000Jan 14 05:26 PM
GILMAN ALFRED GDirectorJan 14Sale300.005,0001,500,0000Jan 14 05:25 PM
Powchik PeterSVP Clinical Development & RegJan 02Sale274.7720,6685,678,96525,447Jan 03 04:10 PM
Powchik PeterSVP Clinical Development & RegDec 31Option Exercise30.6348,0001,470,24073,447Jan 03 04:10 PM
Powchik PeterSVP Clinical Development & RegDec 24Option Exercise21.254,70599,98125,447Dec 26 01:26 PM
Powchik PeterSVP Clinical Development & RegDec 20Sale271.0913336,05520,742Dec 20 05:54 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 19Option Exercise21.254,70599,9811,068,343Dec 20 05:54 PM
Powchik PeterSVP Clinical Development & RegDec 18Option Exercise21.252956,26921,037Dec 20 05:54 PM
STAHL NEILSVP Research and Development SDec 18Option Exercise21.254,70599,98124,391Dec 19 09:49 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrDec 18Option Exercise21.254,70599,98163,102Dec 19 09:49 PM
Van Plew Daniel PSVP & General Mgr Industrial ODec 18Option Exercise21.254,70599,98115,441Dec 19 09:48 PM
Terifay Robert JSVP CommercialDec 18Option Exercise21.254,70599,98120,029Dec 19 09:48 PM
Powchik PeterSVP Clinical Development & RegDec 18Sale270.209,0002,431,80020,742Dec 20 05:54 PM
Powchik PeterSVP Clinical Development & RegDec 17Sale270.0082,16029,742Dec 17 04:16 PM
Powchik PeterSVP Clinical Development & RegDec 16Option Exercise107.1430,6253,281,05638,503Dec 17 04:16 PM
YANCOPOULOS GEORGEPres Regeneron LabsDec 12Option Exercise260.449,5992,499,9641,115,994Dec 13 04:29 PM
VAGELOS P ROYChairman of the BoardDec 02Sale296.119528,1302,257Dec 04 07:34 PM
SING GEORGE LDirectorNov 26Option Exercise15.0110,000150,100122,772Nov 27 04:22 PM
SING GEORGE LDirectorNov 26Sale295.0010,0002,950,000112,772Nov 27 04:22 PM
GOLDSTEIN JOSEPH LDirectorNov 06Sale300.741,000300,7403,000Nov 06 04:17 PM
SCHLEIFER LEONARD SPresident & CEOOct 02Sale313.829,1622,875,25342,087Oct 03 04:14 PM
SCHLEIFER LEONARD SPresident & CEOOct 01Option Exercise111.0129,2763,249,92969,562Oct 03 04:14 PM
BAKER CHARLES ADirectorSep 30Option Exercise19.6915,000295,35024,000Oct 02 04:23 PM
BAKER CHARLES ADirectorSep 30Sale314.0315,0004,710,4399,000Oct 02 04:23 PM
BROWN MICHAEL SDirectorSep 26Option Exercise33.425,000167,10019,662Sep 27 04:07 PM
BROWN MICHAEL SDirectorSep 26Sale309.005,0001,545,00014,662Sep 27 04:07 PM
BROWN MICHAEL SDirectorSep 25Option Exercise33.425,000167,10019,662Sep 27 04:07 PM
BROWN MICHAEL SDirectorSep 25Sale293.645,0001,468,22214,662Sep 27 04:07 PM
SCHLEIFER LEONARD SPresident & CEOSep 19Sale302.67102,94931,159,18142,087Sep 20 04:25 PM
ROBERTS WILLIAMVP Reg Dev & Med SafetySep 18Option Exercise16.8015,000252,00035,644Sep 20 04:24 PM
SCHLEIFER LEONARD SPresident & CEOSep 18Option Exercise9.49218,3892,072,512260,476Sep 20 04:25 PM
ROBERTS WILLIAMVP Reg Dev & Med SafetySep 18Sale304.0015,0004,560,00020,644Sep 20 04:24 PM
Van Plew Daniel PSVP & Gen Mgr IOPSSep 18Sale303.1723,9777,269,04210,736Sep 19 05:16 PM